Theo Jaffee

Yeah.

Yeah.

Well, fantastic.

Well, so, I mean, it looks like you've got a, you've got a deck to take us through.

We're about to get the deck, but feel free to call.

We can kind of riff.

We're just interested to hear what you have to say, Theo.

I mean, you know, so, so Krem, do you want to, do you want to take us off?

What is it?

I mean, maybe start by contextualizing it for us.

What is, what's the context here?

What's the background?

And maybe just to even take a further step back, sorry Theo, but just to take a further step back, Cremo, it's like, okay, so why do we care about that at all?

It's like, we can see the number, am I right in saying the number of, and it's not just medications, right?

You could say more generally, it's like interventions.

So the number of interventions that are kind of making it through clinical trial and being approved for use,

China is leading in that number now.

And like, why does that, you know, in a very like kind of surface level, you know, someone might say, who cares who comes up with it?

Surely the US is going to be the largest market for it.

Surely there's going to be all these process improvements.